| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer
1 company
Michael Rabinowitz last filed a Form 4 in January 2023, as Chief Commercial Officer at ORMP. Michael Rabinowitz's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 126,143 shares of ORMP. The ORMP filings lean toward selling, a net 13,325 shares.
Michael Rabinowitz has 2 Form 4 filings on record from July 2022 to January 2023, all as Chief Commercial Officer at Oramed Pharmaceuticals (ORMP), 2022–2023.
The 3 reported transactions were 2 open-market sales and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $167K.
The only open-market sale was 13,325 shares of ORMP at an average $12.55 on January 3, 2023, about $167K. Twelve months later ORMP was down 81%.
Shares as reported in the last Form 4 for each company; the most recent is from January 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 3, 2023 | ORMP Oramed Pharmaceuticals Inc. | Chief Commercial Officer | Sell | 13,325 | $12.55 | $167,195.04 | -9.6% | -82.2% | -80.9% |